The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials ... testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

and global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...

Revolve Wealth Partners LLC lifted its holdings ... analysts have recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...